For suspected or existing coronary artery disease. ANDA 204514, held by Johns Hopkins Univ. Ammonia N-13.
As of Nov 16, 2026, ANDA 204514 (Ammonia N 13), held by Johns Hopkins Univ, was first approved by FDA on Aug 19, 2014, with 0 approved supplements and 0 published complete response letters.
Ammonia N 13 Injection USP is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection USP is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ammonia N 1330mCi-300mCi/8ML (3.75-37.5mCi/ML) · injectable;intravenous | Ammonia N-13 | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters